Avalyn Pharma(NASDAQ) AVLN

Avalyn Pharma Inc. makes inhaled medicines for rare lung diseases. These treatments help patients who struggle with lung scarring. The company designs drugs to reach the lungs directly.

Medicines That Patients Breathe In

• AP01: Inhaled version of pirfenidone currently in Phase 2b clinical trials for lung scarring; designed to improve patient tolerability.
• AP02: Aerosolized form of nintedanib undergoing Phase 2 testing for patients with idiopathic pulmonary fibrosis.
• AP03: Combined inhaled dose of two antifibrotic drugs scheduled for Phase 1 trials by the end of 2026.

Growing the Clinical Pipeline

• Completed an initial public offering on May 1, 2026, which generated $316.6 million in net proceeds.
• Entered into a licensing agreement with PARI Pharma GmbH in April 2017 to use proprietary nebulizer technology.
• Secured a $30.0 million debt facility with Banc of California in Feb. 2026.
• Expanded its Boston headquarters through a sublease amendment in June 2026 to support increased staff levels.

Precision Delivery Technology

Avalyn utilizes a lung-targeted platform to deliver established respiratory medications directly to the site of disease via specialized nebulizers. This delivery method aims to provide therapeutic benefits while reducing the side effects typically associated with oral versions of these drugs.

Key Financial Figures

• Market capitalization reached $1.7 billion following the company's public debut in 2026.
• Net loss was $28.9 million for the three months ended June 30, 2026.
• Research and development expenses were $24.7 million for the three-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $413.5 million as of June 30, 2026.

The Final Word

Avalyn has evolved from a private research firm into a public clinical-stage developer of inhaled respiratory treatments. Its strategy of optimizing existing medications for direct lung delivery addresses significant unmet needs in the treatment of rare lung diseases.